Harmony Biosciences Holdings, Inc. (HRMY)
42.25
+0.39
(+0.93%)
USD |
NASDAQ |
Sep 04, 16:00
42.18
-0.07
(-0.17%)
Pre-Market: 20:00
Harmony Biosciences Holdings Research and Development Expense (Quarterly) : 46.60M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 46.60M |
| March 31, 2026 | 69.38M |
| December 31, 2025 | 49.93M |
| September 30, 2025 | 54.96M |
| June 30, 2025 | 50.16M |
| March 31, 2025 | 34.54M |
| December 31, 2024 | 34.67M |
| September 30, 2024 | 25.39M |
| June 30, 2024 | 63.58M |
| March 31, 2024 | 22.19M |
| December 31, 2023 | 30.31M |
| September 30, 2023 | 17.50M |
| June 30, 2023 | 14.97M |
| March 31, 2023 | 13.29M |
| December 31, 2022 | 10.09M |
| Date | Value |
|---|---|
| September 30, 2022 | 40.55M |
| June 30, 2022 | 12.67M |
| March 31, 2022 | 7.578M |
| December 31, 2021 | 7.451M |
| September 30, 2021 | 11.74M |
| June 30, 2021 | 6.498M |
| March 31, 2021 | 4.679M |
| December 31, 2020 | 7.619M |
| September 30, 2020 | 4.23M |
| June 30, 2020 | 4.169M |
| March 31, 2020 | 3.431M |
| December 31, 2019 | 7.276M |
| September 30, 2019 | 4.336M |
| June 30, 2019 | 4.993M |
| March 31, 2019 | 52.99M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Liquidia Corp. | 16.88M |
| Repligen Corp. | 14.42M |
| Johnson & Johnson | 3.603B |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| ANI Pharmaceuticals, Inc. | 14.75M |